AU2008297027B2 - Glucose-induced inactivation/degradation-resistant transporter gene and use thereof - Google Patents
Glucose-induced inactivation/degradation-resistant transporter gene and use thereof Download PDFInfo
- Publication number
- AU2008297027B2 AU2008297027B2 AU2008297027A AU2008297027A AU2008297027B2 AU 2008297027 B2 AU2008297027 B2 AU 2008297027B2 AU 2008297027 A AU2008297027 A AU 2008297027A AU 2008297027 A AU2008297027 A AU 2008297027A AU 2008297027 B2 AU2008297027 B2 AU 2008297027B2
- Authority
- AU
- Australia
- Prior art keywords
- polynucleotide
- yeast
- amino acid
- seq
- glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108010078791 Carrier Proteins Proteins 0.000 title claims abstract description 98
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 70
- 239000008103 glucose Substances 0.000 title claims abstract description 70
- 230000015556 catabolic process Effects 0.000 title claims abstract description 50
- 238000006731 degradation reaction Methods 0.000 title claims abstract description 50
- 230000002779 inactivation Effects 0.000 title claims abstract description 40
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 110
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 68
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims abstract description 51
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims abstract description 51
- 238000000034 method Methods 0.000 claims abstract description 49
- 235000013334 alcoholic beverage Nutrition 0.000 claims abstract description 25
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 14
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 14
- 108091033319 polynucleotide Proteins 0.000 claims description 88
- 239000002157 polynucleotide Substances 0.000 claims description 88
- 102000040430 polynucleotide Human genes 0.000 claims description 88
- 239000002773 nucleotide Substances 0.000 claims description 38
- 125000003729 nucleotide group Chemical group 0.000 claims description 38
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 25
- 239000013598 vector Substances 0.000 claims description 23
- 230000014509 gene expression Effects 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 10
- 235000014101 wine Nutrition 0.000 claims description 5
- 235000021577 malt beverage Nutrition 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 150000008494 α-glucosides Chemical class 0.000 claims 5
- 229930182478 glucoside Natural products 0.000 claims 2
- 150000008131 glucosides Chemical class 0.000 claims 2
- 230000000052 comparative effect Effects 0.000 claims 1
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 abstract description 18
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 abstract description 18
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 abstract description 18
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 abstract description 18
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 abstract description 14
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 101
- 150000001413 amino acids Chemical group 0.000 description 57
- 235000018102 proteins Nutrition 0.000 description 31
- 239000002609 medium Substances 0.000 description 27
- 101100394866 Arabidopsis thaliana HIPP47 gene Proteins 0.000 description 20
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 19
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 19
- 239000013612 plasmid Substances 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 101100075883 Saccharomyces cerevisiae MAL61 gene Proteins 0.000 description 15
- 235000000346 sugar Nutrition 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 238000000855 fermentation Methods 0.000 description 13
- 230000004151 fermentation Effects 0.000 description 13
- 101100290064 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MAL31 gene Proteins 0.000 description 12
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 12
- 230000012010 growth Effects 0.000 description 11
- 101150050575 URA3 gene Proteins 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000002585 base Substances 0.000 description 8
- 235000013405 beer Nutrition 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 150000008163 sugars Chemical class 0.000 description 8
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 7
- 229940041514 candida albicans extract Drugs 0.000 description 7
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 239000012138 yeast extract Substances 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 5
- 101100075884 Saccharomyces cerevisiae MAL62 gene Proteins 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- -1 maltose Chemical class 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241000235070 Saccharomyces Species 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 229930182536 Antimycin Natural products 0.000 description 3
- 101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 101100075885 Saccharomyces cerevisiae MAL63 gene Proteins 0.000 description 3
- 241001123227 Saccharomyces pastorianus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 108010028144 alpha-Glucosidases Proteins 0.000 description 3
- CQIUKKVOEOPUDV-IYSWYEEDSA-N antimycin Chemical compound OC1=C(C(O)=O)C(=O)C(C)=C2[C@H](C)[C@@H](C)OC=C21 CQIUKKVOEOPUDV-IYSWYEEDSA-N 0.000 description 3
- 229960005261 aspartic acid Drugs 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 229960002989 glutamic acid Drugs 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 229960003136 leucine Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229960004452 methionine Drugs 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 229960001153 serine Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 229960002898 threonine Drugs 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- 229960004295 valine Drugs 0.000 description 3
- 235000015041 whisky Nutrition 0.000 description 3
- 239000007206 ypm medium Substances 0.000 description 3
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- OWEFQTXQEHYDEJ-UHFFFAOYSA-N 2,3-dihydroxypropanal diphosphono hydrogen phosphate Chemical compound OCC(O)C=O.OP(O)(=O)OP(O)(=O)OP(O)(O)=O OWEFQTXQEHYDEJ-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 2
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 2
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- RWWZYORFHGIOOC-UHFFFAOYSA-N 5-chloro-6-[4-(2-hydroxyethyl)piperidin-1-yl]-1h-pyrimidine-2,4-dione Chemical compound C1CC(CCO)CCN1C1=NC(O)=NC(O)=C1Cl RWWZYORFHGIOOC-UHFFFAOYSA-N 0.000 description 2
- MKPCNMXYTMQZBE-UHFFFAOYSA-N 7h-purin-6-amine;sulfuric acid;dihydrate Chemical compound O.O.OS(O)(=O)=O.NC1=NC=NC2=C1NC=N2.NC1=NC=NC2=C1NC=N2 MKPCNMXYTMQZBE-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 108010001496 Galectin 2 Proteins 0.000 description 2
- 102100021735 Galectin-2 Human genes 0.000 description 2
- 101000962438 Homo sapiens Protein MAL2 Proteins 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 2
- 229930182844 L-isoleucine Natural products 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- 235000019454 L-leucine Nutrition 0.000 description 2
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 2
- 229930195722 L-methionine Natural products 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102100039191 Protein MAL2 Human genes 0.000 description 2
- 101150014136 SUC2 gene Proteins 0.000 description 2
- 101100290054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MAL12 gene Proteins 0.000 description 2
- 101100075879 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MAL32 gene Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- OSQPUMRCKZAIOZ-UHFFFAOYSA-N carbon dioxide;ethanol Chemical compound CCO.O=C=O OSQPUMRCKZAIOZ-UHFFFAOYSA-N 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000005360 mashing Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 235000019992 sake Nutrition 0.000 description 2
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
- YOFPFYYTUIARDI-ZCFIWIBFSA-N (2r)-2-aminooctanedioic acid Chemical compound OC(=O)[C@H](N)CCCCCC(O)=O YOFPFYYTUIARDI-ZCFIWIBFSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- GVEZIHKRYBHEFX-MNOVXSKESA-N 13C-Cerulenin Natural products CC=CCC=CCCC(=O)[C@H]1O[C@@H]1C(N)=O GVEZIHKRYBHEFX-MNOVXSKESA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000349731 Afzelia bipindensis Species 0.000 description 1
- 101100433757 Arabidopsis thaliana ABCG32 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 101150085920 MAL61 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- KNTFCRCCPLEUQZ-VKHMYHEASA-N O-methylserine Chemical compound COC[C@H](N)C(O)=O KNTFCRCCPLEUQZ-VKHMYHEASA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 101100054296 Oryza sativa subsp. japonica ABCG37 gene Proteins 0.000 description 1
- 101100107593 Oryza sativa subsp. japonica ABCG40 gene Proteins 0.000 description 1
- 101150084044 P gene Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108091006243 SLC7A13 Proteins 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 101100491255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YAP1 gene Proteins 0.000 description 1
- 244000253724 Saccharomyces cerevisiae S288c Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100023135 Solute carrier family 7 member 13 Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- DRQXUCVJDCRJDB-UHFFFAOYSA-N Turanose Natural products OC1C(CO)OC(O)(CO)C1OC1C(O)C(O)C(O)C(CO)O1 DRQXUCVJDCRJDB-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- GVEZIHKRYBHEFX-UHFFFAOYSA-N caerulein A Natural products CC=CCC=CCCC(=O)C1OC1C(N)=O GVEZIHKRYBHEFX-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- GVEZIHKRYBHEFX-NQQPLRFYSA-N cerulenin Chemical compound C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O GVEZIHKRYBHEFX-NQQPLRFYSA-N 0.000 description 1
- 229950005984 cerulenin Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- BBJIPMIXTXKYLZ-UHFFFAOYSA-N isoglutamic acid Chemical compound OC(=O)CC(N)CC(O)=O BBJIPMIXTXKYLZ-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 229910001416 lithium ion Inorganic materials 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
- C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12C—BEER; PREPARATION OF BEER BY FERMENTATION; PREPARATION OF MALT FOR MAKING BEER; PREPARATION OF HOPS FOR MAKING BEER
- C12C12/00—Processes specially adapted for making special kinds of beer
- C12C12/002—Processes specially adapted for making special kinds of beer using special microorganisms
- C12C12/004—Genetically modified microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12C—BEER; PREPARATION OF BEER BY FERMENTATION; PREPARATION OF MALT FOR MAKING BEER; PREPARATION OF HOPS FOR MAKING BEER
- C12C12/00—Processes specially adapted for making special kinds of beer
- C12C12/002—Processes specially adapted for making special kinds of beer using special microorganisms
- C12C12/006—Yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
- C12G1/00—Preparation of wine or sparkling wine
- C12G1/02—Preparation of must from grapes; Must treatment and fermentation
- C12G1/0203—Preparation of must from grapes; Must treatment and fermentation by microbiological or enzymatic treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
- C12G2200/00—Special features
- C12G2200/11—Use of genetically modified microorganisms in the preparation of wine
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to a glucose-induced inactivation/degradation resistant transporter gene and use thereof, and more particularly to a brewery yeast having excellent assimilability of oligosaccharides (maltose, maltotriose, etc.), an alcoholic beverage produced using the yeast, and so on. In particular, the present invention relates to a glucose-induced inactivation/degradation resistant transporter such as Mal2Ip, etc., a gene encoding the same, a method of producing an alcoholic beverage using the same; and so on.
Description
DESCRIPTION GLUCOSE-INDUCED INACTIVATION/DEGRADATION-RESISTANT TRANSPORTER GENE AND USE THEREOF 5 TECHNICAL FIELD The present invention relates to a glucose-induced inactivation/degradation transporter gene and use thereof, and more particularly to a brewing yeast having an excellent assimilability of oligosaccharides (maltose, maltotriose, etc.), an alcoholic 10 beverage prepared using the yeast, a method of producing the alcoholic beverage, and so on. BACKGROUND ART In the production of malt fermented beverages such as beer, happoshu 15 (low-malt beer), whisky, etc., the major three sugars contained in a wort prepared by mashing a malt, etc. are glucose, maltose and maltotriose. The ratio of these malt-derived sugars can be somewhat varied depending on the mashing process and may be approximately 1:5:1, since the ratio does not change significantly when enzyme preparations, glycosylated starch, etc. are not added. Among them, glucose 20 is a monosaccharide and preferentially assimilated as a sugar most favored by yeast. Yeast has numerous genes suppressed in the presence of glucose during the transcription process. This regulatory suppression is called glucose repression. Several transporters required for the uptake of maltose or maltotriose into yeast all undergo this repression. It is known that some of these gene products which 25 undergo glucose repression are inactivated in the presence of glucose even after translation. c-Glucoside transporters are also within this type and known to be rapidly degraded in the presence of glucose. The first step of assimilation of maltose or maltotriose is its uptake into yeast cells by these transporters and when transporters are degraded, assimilation of these sugars is discontinued. This is the 30 reason why the expression of transporter is called a rate-determining step for assimilation. Non-Patent Document 1: Brondijk, T. H., van der Rest, M. E., Pluim, D., de Vries, Y. de., Stingl, K., Poolman, B. and Konings, W. N. (1998) J. Biol. Chem., 273 (25), 15352-15357 35 Non-Patent Document 2: Medintz, I., Wang, X., Hradek, T. and Michels, C. A. 1 (2000) Biochemistry, 39 (15), 4518-4526 Non-Patent Document 3: Gadura, N. and Michels, C. A. (2006) Curr. Genet., 50 (2), 101-114 5 DISCLOSURE OF INVENTION Under such situations, it has been desired to provide a yeast bearing an oligosaccharide transporter less susceptible to glucose-induced inactivation or degradation and having an improved assimilation of oligosaccharides such as maltose, etc. 10 The present inventors have made extensive efforts to solve the foregoing problems. As a result, the inventors have developed a novel method of screening a transporter, which is less susceptible to glucose-induced inactivation or degradation (hereinafter referred to as "glucose-induced inactivation/degradation-resistant transporter") or a yeast expressing the transporter and based on the screening method, 15 found the glucose-induced inactivation/degradation-resistant transporter or a yeast bearing the same. The present invention has thus been accomplished. In other words, the present invention relates to a gene encoding the glucose-induced inactivation/degradation-resistant transporter, a transporter protein encoded by the gene, a transformed yeast in which expression of the gene is 20 regulated, a method of producing an alcoholic beverage which comprises using the yeast in which expression of the gene is regulated, etc. More specifically, the present invention provides the polynucleotides given below, vectors comprising the polynucleotides, transformed yeasts in which the vectors are introduced, and a method of producing alcoholic beverages using these transformed yeasts. 25 (1) A polynucleotide selected from the group consisting of (a) to (f) below: (a) a polynucleotide comprising a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 1; (b) a polynucleotide comprising a polynucleotide encoding a protein consisting of the amino acid sequence of SEQ ID NO: 2; 30 (c) a polynucleotide comprising a polynucleotide consisting of an amino acid sequence wherein 1 to 15 amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 2, and encoding a transporter protein having a resistance to glucose-induced inactivation/degradation; (d) a polynucleotide comprising a polynucleotide comprising an amino acid sequence 35 having an identity of at least 90% with the amino acid sequence of SEQ ID NO: 2, 2 and encoding a transporter protein having a resistance to glucose-induced inactivation/degradation; (e) a polynucleotide comprising a polynucleotide hybridizing with a polynucleotide consisting of a nucleotide sequence complementary to the nucleotide sequence of 5 SEQ ID NO: 1 under stringent conditions, and encoding a transporter protein having a resistance to glucose-induced inactivation/degradation; and, (f) a polynucleotide comprising a polynucleotide hybridizing with a polynucleotide consisting of a nucleotide sequence complementary to the nucleotide sequence of a polynucleotide encoding a protein consisting of the amino acid sequence of SEQ ID 10 NO: 2 under stringent conditions, and encoding a transporter protein having a resistance to glucose-induced inactivation/degradation. (2) The polynucleotide according to (1), which is selected from the group consisting of (g) to (i) below: (g) a polynucleotide comprising a polynucleotide encoding a transporter protein 15 consisting of the amino acid sequence of SEQ ID NO: 2, or the amino acid sequence of SEQ ID NO: 2 wherein I to 5 amino acids are deleted, substituted, inserted and/or added in the amino acid sequence, and having a resistance to glucose-induced inactivation/degradation; (h) a polynucleotide comprising a polynucleotide encoding a transporter protein 20 comprising the amino acid sequence having an identity of at least 97% with the amino acid sequence of SEQ ID NO: 2, and having a resistance to glucose-induced inactivation/degradation; and, (i) a polynucleotide comprising a polynucleotide hybridizing with a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 1 or with a polynucleotide 25 consisting of a nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO: I under high stringent conditions, and encoding a transporter protein having a resistance to glucose-induced inactivation/degradation. (3) The polynucleotide according to (1) or (2), comprising a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 1. 30 (4) The polynucleotide according to (1) or (2), comprising a polynucleotide encoding a protein consisting of the amino acid sequence of SEQ ID NO: 2. (5) The polynucleotide according to any one of (1) to (4), which is a DNA. (6) A protein encoded by the polynucleotide according to any one of (1) to (5). 35 (7) A vector comprising the polynucleotide according to any one of (1) to 3 4 (8) A transformed yeast introduced with the vector according to (7). (9) The yeast for brewing according to (8), wherein oligosaccharide assimilability is improved by introducing the vector according to (7). (10) The yeast for brewing according to (8), wherein oligosaccharide assimilability is 5 improved by increasing the expression level of the protein according to (6). (11) A method of producing an alcoholic beverage which comprises using the yeast according to any one of (8) to (10). (12) The method of producing an alcoholic beverage according to (11), wherein the alcoholic beverage brewed is a malt beverage. 10 (13) The method of producing an alcoholic beverage according to (12), wherein the alcoholic beverage brewed is wine. (14) An alcoholic beverage produced by the method according to any one of (11) to (13). [0006A] Any discussion of documents, acts, materials, devices, articles or the like 15 which has been included in the present specification is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application. [0006B] Throughout this specification the word "comprise", or variations such as 20 "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps. [0007] The use of the yeast in accordance with the present invention provides the advantage that the fermentation rate of moromi mash containing oligosaccharides such 25 as maltose, etc. can be increased. The transporter gene in accordance with the present invention can be introduced into any of brewing yeasts or laboratory yeasts. It is effective especially in the case where oligosaccharides (maltose, maltotriose, turanose, trehalose, etc.) which can be taken up by the transporter in accordance with the present invention are contained in a crude fermentation liquor abundant in monosaccharides 30 such as glucose, fructose, etc. 628687 1 4A BRIEF DESCRIPTION OF DRAWINGS [0008] FIG 1 shows the differences in growth between laboratory yeasts in the presence of 2-deoxyglucose. FIG 2 shows the nucleotide sequence of MAL21 gene. 5 FIG. 3 shows the amino acid sequence of Mal2l p gene. FIG 4-1 shows the alignment of the amino acid sequence of Mal2 1 p/Mal3 1 p/Mal6l p. FIG 4-2 shows the alignment of the nucleotide sequence of Mal2Ip/Mal3 1p/Mal61p. 10 FIG 4-3 is continued from FIG 4-2. FIG 4-4 is continued from FIG. 4-3. 628687 1 FIG 5 shows the differences in growth among strains bearing MAL21/MAL61gene in the presence of 2-deoxyglucose. FIG 6 shows the degradation rate of Mal2lp and Mal61p in the presence of glucose. 5 FIG 7 shows the growth of MAL21/MAL61 gene-highly expressed laboratory strains in a maltose medium. FIG. 8 shows the maltose fermentation rates of MAL21 gene-highly expressed bottom-fermenting beer yeast strains in happoshu (low-malt beer) or in happoshu (glucose-rich) wort. 10 FIG 9 shows the maltose fermentation rates in the wort of top-fermenting beer yeasts in which the Mal2lp transporter is highly expressed. FIG 10 shows the construction of plasmid pJHXSB. FIG 11 shows the construction of plasmid pJHIXSB. FIG 12 shows the construction of plasmid pYCGPY. 15 FIG 13 shows the construction of plasmid pUP3GLP. BEST MODES FOR CARRYING OUT THE INVENTION Based on the idea that if glucose-induced inactivation or degradation of a post-translational transporter can be regulated, maltose and maltotriose can be more 20 efficiently assimilated by a yeast in the presence of glucose, the present inventors have made extensive efforts and as a result, found Mal2lp from the natural world, which is an ct-glucoside transporter less susceptible to degradation, and confirmed that the degradation rate of Mal2lp is extremely slow when compared to other transporters. 25 It has also been succeeded that by highly expressing the newly obtained transporter less susceptible to glucose-induced inactivation or degradation, the growth rate could be increased actually in a maltose medium. In addition, the assimilation rate of maltose could be increased in beer brewing. The present invention has been accomplished based on this idea and the results of studies. 30 In the present invention, SEQ ID NOS: 1 to 6 represent the nucleotide sequences of the following genes or the amino acid sequences of the following transporters. [SEQ ID NO: 1] Nucleotide sequence of MAL21 35 [SEQ ID NO: 2] Amino acid sequence of Mal2lp c-glucoside transporter 5 [SEQ ID NO: 3] Nucleotide sequence of MAL31 [SEQ ID NO: 4] Amino acid sequence of Mal3 Ip a-glucoside transporter [SEQ ID NO: 5] Nucleotide sequence of MAL61 [SEQ ID NO: 6] Amino acid sequence of Mal6Ip a-glucoside transporter 5 As used herein, the term "c-glucoside transporter" refers to a protein associated with a-glucoside transport and such ca-glucoside transporters include a maltose transporter, a maltotriose transporter, etc. 10 1. Polynucleotide of the invention First, the present invention provides (a) a polynucleotide comprising the polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 1; and (2) a polynucleotide comprising the polynucleotide encoding a protein consisting of the amino acid sequence of SEQ ID NO: 2. The polynucleotide may be DNA or RNA. 15 The polynucleotide intended in the present invention is not limited to polynucleotides encoding the proteins having the sequences described above but includes other polynucleotides encoding proteins functionally equivalent to the proteins having the above sequences. The functionally equivalent proteins include, for example, (c) a transporter protein comprising an amino acid sequence in which 1 20 to 15 (preferably I to 14, 1 to 13, i to 12, I to 11, I to 10, 1 to 9, I to 8, 1 to 7, 1 to 6, 1 to 5, i to 4, 1 to 3, 1 to 2 or 1) amino acids are deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 2, and having the resistance to glucose-induced inactivation/degradation. Such proteins include a transporter protein comprising an amino acid 25 sequence in which, for example, I to 14, I to 13, 1 to 12, I to 11, 1 to 10, 1 to 9, i to 8, 1 to 7, 1 to 6 (1 to several), I to 5, 1 to 4, 1 to 3, 1 to 2 or 1 amino acid residue is deleted, substituted, inserted and/or added in the amino acid sequence of SEQ ID NO: 2, and having the resistance to glucose-induced inactivation/degradation. In general, the smaller number of the deletion, substitution, insertion and/or addition of 30 the amino acid residues above is preferred. Such proteins include (d) transporter proteins comprising an amino acid sequence having the identity of at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.1%, at least about 99.2%, at least about 99.3%, at least about 35 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 6 99.8% and at least about 99.9%, with the amino acid sequence of SEQ ID NO: 2, and having the resistance to glucose-induced inactivation/degradation. In general, the larger numerical value of the homology described above is more preferred. 5 <Assessment of resistance to glucose-induced inactivation/degradation> According to the present invention, the resistance to glucose-induced inactivation/degradation can be evaluated, for example, by the following procedures. First, it is confirmed that a strain expressing each transporter protein is able to grow in a 2% maltose-supplemented synthetic complete medium (SCM) containing 0 to 10 2.0 mM of 2-deoxyglucose (6.7 g/L of yeast nitrogen base w/o amino acids, 20 g/L of maltose, 20 mg/ml of adenine sulfate, 20 mg/ml of uracil, 20 mg/ml of L-tryptophan, 20 mg/ml of L-histidine hydrochloride, 20 mg/ml of L-arginine hydrochloride, 20 mg/ml of L-methionine, 30 mg/ml of L-tyrosine, 30 mg/ml of L-leucine, 30 mg/ml of L-isoleucine, 30 mg/ml of L-lysine hydrochloride, 50 mg/ml 15 of L-phenylalanine, 100 mg/ml of L-glutamic acid, 100 mg/ml of L-aspartic acid, 150 mg/ml of L-valine, 200 mg/ml of L-threonine and 400 mg/ml of L-serine), or in a maltose, etc. minimum medium containing 0 to 2 mM of 2-deoxyglucose (6.7 g/L of yeast nitrogen base w/o amino acids, 20 g/L of maltose, etc.; if the transformant is auxotrophic, also containing the nutrients), to select the strain in which the 20 transporter retains the maltose uptake activity in yeasts even where the signal of glucose-induced inactivation/degradation generates. Next, this strain is inoculated into YPD (10 g/L of yeast extract, 20 g/L of polypeptone and 20 g/L of glucose) followed by shaking the culture at 30'C overnight. The culture broth is inoculated into a YPM medium (10 g/L of yeast extract, 20 g/L of polypeptone and 5 g/L of 25 maltose) followed by shake culture at 30'C for 2.5 hours to reach OD660 = 1.0. The cells are then collected. The 60 OD660 units of cells are measured and suspended in 30 ml of a medium for degradation rate measurement (1.7 g/L of yeast nitrogen base w/o amino acids and ammonia, 20 g/L of glucose and 25 pg/L of cycloheximide) preincubated at 30'C, followed by incubation at 30'C. The cell 30 suspension is sampled by 5 ml at an appropriate time (0, 10, 20, 30 and 40 minutes or 0, 30, 60, 90 and 120 minutes). After the suspension is centrifuged immediately thereafter, the supernatant is discarded and the cells are frozen using an ethanol-dry ice. The transporter protein is isolated from the frozen cells in a conventional manner and the intensity of the protein band is measured to determine the half life 35 from its diminution rate. The transporter protein preferably used in the present 7 invention has the half life of 2 times or more, 3 times or more, 4 times or more, 5 times or more, 6 times or more or 8 times or more, than that of, e.g., Mal3 Ip or Mal6lp. The present invention further provides (e) a polynucleotide comprising a 5 polynucleotide hybridizing with a polynucleotide consisting of a nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO: 1 under stringent conditions, and encoding a transporter protein having a resistance to glucose-induced inactivation/degradation; and, (f) a polynucleotide comprising a polynucleotide hybridizing with a polynucleotide consisting of a nucleotide sequence 10 complementary to the nucleotide sequence of a polynucleotide encoding the protein consisting of the amino acid sequence of SEQ ID NO: 2 under stringent conditions, and encoding a transporter protein having a resistance to glucose-induced inactivation/degradation. The polynucleotide which is preferred in the present invention includes the 15 polynucleotides defined in (a) through (f) above, the polynucleotide comprising a polynucleotide encoding a protein consisting of the amino acid sequence of SEQ ID NO: 2, and the polynucleotide comprising a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 1, more preferably the polynucleotide defined by SEQ ID NO: 1. 20 As used herein, the term "polynucleotide hybridizing under stringent conditions" refers to a polynucleotide (such as DNA) obtained by the colony hybridization technique, the plaque hybridization technique, the Southern hybridization technique or the like, using as a probe all or a portion of a polynucleotide consisting of a nucleotide sequence complementary to the nucleotide 25 sequence of SEQ ID NO: 1 or a polynucleotide encoding the amino acid sequence of SEQ ID NO: 2. For the hybridization, there may be used methods described in, for example, Molecular Cloning, 3rd Ed., Current Protocols in Molecular Biology, John Wiley & Sons, 1987-1997, etc. As used herein, the term "stringent conditions" may be any of low stringent 30 conditions, medium stringent conditions and high stringent conditions. The term "low stringent conditions" refers to conditions of, e.g., 5 x SSC, 5 x Denhardt's solution, 0.5% SDS, 50% formamide and 32*C. The term "medium stringent conditions" refers to conditions of, e.g., 5 x SSC, 5 x Denhardt's solution, 0.5% SDS, 50% formamide and 42*C. The term "high stringent conditions" refers to 35 conditions of, e.g., 5 x SSC, 5 x Denhardt's solution, 0.5% SDS, 50% formamide and 8 50*C. It can be expected under these conditions that DNAs having a higher homology are efficiently obtained as the temperature becomes higher. However, there are several factors that might affect the stringency of hybridization to be considered and such factors include temperature, probe concentration, probe length, 5 ionic strength, time, salt concentration, etc. Those skilled in the art can suitably choose these factors to achieve the same stringencies. In the case of using commercially available kits for the hybridization, for example, Alkphos Direct Labeling Reagents (manufactured by Amersham Pharmacia) can be used. In this case, the hybridized DNA can be detected by 10 incubating with a labeled probe overnight and washing the membrane with a primary wash buffer containing 0.1% (w/v) SDS at 55'C, according to the protocol attached to the kit. Other DNAs that can be hybridized include DNAs having the identity of at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least 15 about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99. 1%, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 99.8%, or at least about 99.9%, with the DNA encoding the amino acid sequence of SEQ ID NO: 2 or 4, as calculated by a homology search 20 software such as FASTA, BLAST, etc. using default parameters. The identity of amino acid sequences or nucleotide sequences can be determined using the algorithm BLAST by Karlin and Altschul (Proc. Nati. Acad. Sci. USA, 87: 2264-2268, 1990; Proc. Nati. Acad. Sci. USA, 90: 5873, 1993). Based on the algorithm BLAST, programs called BLASTN and BLASTX have been developed 25 (Altschul S. F., et al., J. Mol. Biol. 215: 403, 1990). When a nucleotide sequence is analyzed using BLASTN, the parameters are set to, for example, score = 100 and word length = 12. When an amino acid sequence is analyzed using BLASTX, the parameters are set to, for example, score = 50 and word length = 3. When BLAST and Gapped BLAST programs are used, default parameters for each of the programs 30 are employed. 2. Protein of the invention The present invention also provides the protein encoded by any one of the polynucleotides (a) through (i) described above. Preferred examples of the proteins 35 of the present invention are transporter proteins consisting of the amino acid 9 sequence of SEQ ID NO: 2, in which I to 15 amino acids (preferably, I to 14, 1 to 13, Ito 12, Ito 11, Ito 10, ito 9, Ito 8, ito 7, Ito 6, ito 5, Ito 4, Ito 3, Ito 2, or 1) are deleted, substituted, inserted and/or added in the amino acid sequence, and having the resistance to glucose-induced inactivation/degradation. 5 Such proteins include transporter proteins consisting of the amino acid sequence of SEQ ID NO: 2, in which the aforesaid numbers of amino acid residues are deleted, substituted, inserted and/or added in the amino acid sequence, and having the resistance to glucose-induced inactivation/degradation. Such transporter proteins include transporter proteins having the amino acid sequence which has the 10 homology described above to the amino acid sequence of SEQ ID NO: 2, and having the resistance to glucose-induced inactivation/degradation. These proteins can be obtained by site-directed mutagenesis described in Molecular Cloning, 3rd ed., Current Protocols in Molecular Biology, Nuc. Acids. Res., 10, 6487 (1982), Proc. Nati. Acad. Sci. USA, 79, 6409 (1982), Gene, 34, 315 (1985), Nuc. Acids. Res., 13, 15 4431 (1985), Proc. Natl. Acad. Sci. USA, 82, 488 (1985), etc. What is meant by I to 15 amino acids (preferably, I to 14, 1 to 13, 1 to 12, 1 to ll, ito 10, Ito 9, Ito 8, Ito 7, ito 6, ito 5, ito 4, ito 3, I to 2, or 1) being deleted, substituted, inserted and/or added in the amino acid sequence of proteins in accordance with the polynucleotide of the present invention refers to that the deletion, 20 substitution, insertion and/or addition of I to 15, i to 14, 1 to 13, 1 to 12, 1 to 11, 1 to 10, 1 to 9, 1 to 8, i to 7, I to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1 amino acid residue(s) take place at optional positions in I to 15, 1 to 14, 1 to 13, 1 to 12, I to 11, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2, or I amino acid sequence in the same sequence. Among the deletion, substitution, insertion and/or addition, two or 25 more events may take place concurrently. Examples of the amino acid residues which are mutually substitutable are given below. The amino acid residues in the same group are mutually substitutable. Group A: leucine, isoleucine, norleucine, valine, norvaline, alanine, 2-aminobutanoic acid, methionine, o-methylserine, t-butylglycine, t-butylalanine and 30 cyclohexylalanine; Group B: aspartic acid, glutamic acid, isoaspartic acid, isoglutamic acid, 2-aminoadipic acid and 2-aminosuberic acid; Group C: asparagine and glutamine; Group D: lysine, arginine, ornithine, 2,4-diaminobutanoic acid and 2,3-diaminopropionic acid; Group E: proline, 3-hydroxyproline and 4-hydroxyproline; Group F: serine, threonine and homoserine; and Group G: 35 phenylalanine and tyrosine. 10 The protein of the present invention can also be produced by chemical synthesis methods such as the Fmoc method (fluorenylmethyloxycarbonyl method), the tBoc method (t-butyloxycarbonyl method) or the like. In addition, peptide synthesizers available from, for example, Advanced ChemTech, Perkin-Elmer, 5 Pharmacia, Protein Technology Instrument, Synthecell-Vega, PerSeptive, Shimadzu Corp. can also be used for the chemical synthesis. 3. Vector of the invention and yeast transformed with the vector Next, the present invention provides the vector comprising the 10 polynucleotide described above. Preferably, the vector of the present invention comprises the polynucleotide (DNA) described in any one of (a) through (i) described above, the polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 1 or the polynucleotide encoding the protein consisting of the amino acid sequence of SEQ ID NO: 2. The vector of the present invention is usually so 15 constructed that the vector comprises (x) a promoter capable of transcription in yeast cells, (y) the polynucleotide (DNA) described above linked to the promoter in a sense direction or antisense direction and (z) an expression cassette comprising as the constituting element a signal that functions in yeast with respect to the transcription termination and polyadenylation of RNA molecules. When the protein of the 20 present invention is highly expressed, it is preferred to introduce the polynucleotide (DNA) described in any one of (a) through (i) described above in a sense direction relative to the promoter so as to enhance expression of these polynucleotides. As the vector used to introduce into the yeast, any of multicopy (YEp type), single-copy (YCp type) and chromosomal integration (YIp type) plasmids are 25 available. For example, YEp24 (J. R. Broach et al., Experimental Manipulation of Gene Expression, Academic Press, New York, 83, 1983) is known as the YEp type vector; YCp50 (M. D. Rose et al., gene, 60, 237, 1987) is known as the YCp type vector; and YIp5 (K. Struhl, et al., Proc. Natl. Acad. Sci. USP, 76, 1035, 1979) is known as the Ylp type vector, all of which are readily available. It is also possible 30 to use plasmids such as chromosomal integration type pUP3GLP (Omura, F. et al., FEMS Microbiol. Lett., 194, 207, 2001) (FIG. 13) or pJHIXSB (FIG 11), single-copy replicating type pYCGPY (Kodama, Y et al., Appl. Environ. Microbiol., 67, 3455, 2001) (FIG. 12) or pJHXSB (FIG. 10), etc. Promoters/terminators for regulating gene expression in yeasts may be used 35 in any optional combination as far as they function in brewing yeasts and are 11 independent from concentrations of the components such as sugar or amino acids in a moromi mash. For example, a promoter for glyceraldehyde-3 -phosphate dehydrogenase gene (TDH3), a promoter for phosphoglycerate kinase gene (PGK1), etc. can be used. These genes are already cloned and described in, e.g., M. F. Tuite, 5 et al., EMBO J., 1, 603 (1982), and easily available by known methods. The promoters used in the expression vector can be effectively replaced into those having a suitable transcription activity depending on the sugar components or sugar concentrations of moromi mash or by combining a plurality of transporters, etc. Since any auxotrophic marker cannot be used for brewing yeasts as a 10 selection marker used for the transformation, there are used geneticin resistant gene (G418r), copper resistant gene (CUP1) (Marin, et al., Proc. Nati. Acad. Sci. USA, Vol. 81, p 337 (1984)), cerulenin resistant gene (fas2m, PDR4) (J. Inokoshi, et al., Seikagaku, Vol. 64, p 660 (1992); Hussain, M. et al., Gene Vol. 101, p 149 (1991)), and the like. The vector constructed as described above is introduced into the host 15 yeast. Examples of the host yeast used in the present invention include any yeast which can be used for brewing, for example, brewing yeasts for beer, wine, sake, etc. Specifically, yeasts belonging to the genus Saccharomyces can be used. According to the present invention, beer yeasts, for example, Saccharomyces pastorianus 20 W34/70, etc., Saccharomyces carlsbergensis NCYC453, NCYC456, etc., Saccharomyces cerevisiae NBRC1951, NBRC 1952, NBRC 1953, NBRC 1954, etc., can be used. In addition, whisky yeasts such as Saccharomyces cerevisiae NCYC90, etc., wine yeasts such as wine yeast Nos. 1, 3, 4, etc. from the Brewing Society of Japan, and sake yeasts such as sake yeast Nos. 7, 9, etc. from the Brewing 25 Society of Japan can also be used but there is no limitation thereto. In the present invention, preferably used are beer yeasts, e.g., Saccharomyces pastorianus. Chromosomal DNAs used to prepare the respective transporter genes described herein are not limited to strains such as Saccharomyces cerevisiae ATCC 20598, ATCC 96955, etc., and may be prepared from any yeast so long as they are 30 yeast bearing such genes and belonging to Saccharomyces cerevisiae. For the yeast transformation, there can be used publicly known methods generally used. The methods that can be used for transformation include, but not limited to, an electroporation method (Meth. Enzym., 194, 182 (1990)), a spheroplast method (Proc. Natl. Acad. Sci. USA, 75, 1929 (1978)), the lithium acetate method (J. 35 Bacteriology, 153, 163 (1983)), and methods described in Proc. Nat]. Acad. Sci. USA, 12 75, 1929 (1978), Methods in Yeast Genetics, 2000 Edition: A Cold Spring Harbor Laboratory Course Manual, and the like. The transformants can be selected in a uracil-free agar medium by incorporating a gene complementing a host auxotrophy such as URA3 into an 5 expression plasmid. Alternatively, by incorporating a drug resistant gene, for example, drug resistant gene YAPI against cycloheximide or geneticin resistant gene G418R into the expression plasmid, the transformants can be selected on a medium containing cycloheximide (e.g., 0.3 pg/ml) or geneticin (e.g., 300 pg/ml). More specifically, a host yeast is cultured to reach an OD600 value between 10 1 and 6 in a standard yeast nutrition medium (e.g., YEPD medium: Genetic Engineering, Vol. 1, Plenum Press, New York, 17 (1979)), etc.). This culture yeast is collected by centrifugation, washed and pre-treated with an alkali metal ion, preferably a lithium ion, at a concentration of approximately 1 to 2 M. After the cells are allowed to stand at about 30'C for about 60 minutes, it is allowed to stand 15 with a DNA to be introduced (about 1 to 20 pg) at about 30'C for about further 60 minutes. Polyethylene glycol, preferably polyethylene glycol of about 4,000 daltons, is added to reach the final concentration of about 20% to 50%. After allowing to stand at about 30'C for about 30 minutes, the cells are heat-treated at about 42 0 C for about 5 minutes. Preferably, this cell suspension is washed with a 20 standard yeast nutrition medium, added to a predetermined amount of fresh standard yeast nutrition medium and allowed to stand at about 30*C for about 60 minutes. Thereafter, it is spreaded onto a standard agar medium supplemented with an antibiotic or the like used as a selection marker to obtain the transformant. Other general cloning techniques can be found in, for example, Molecular 25 Cloning, 3rd Ed., Methods in Yeast Genetics, A laboratory manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY), etc. 4. Method of producing alcoholic beverages of the invention and alcoholic beverages produced by the method 30 The vector of the present invention described above is introduced into a yeast suitable for brewing a target alcoholic beverage. Using this yeast, an alcoholic beverage having a characteristic amino acid composition can be produced. The target alcoholic beverages include, for example, but not limited to, beer, wine, whisky, sake and the like. 35 In producing these alcoholic beverages, known techniques can be used 13 except that the brewing yeast obtained in the present invention is used in place of its parent strain. Accordingly, raw materials, manufacturing facilities, manufacturing control, etc. may be exactly the same as those used for the known methods and there is no increase in the cost of producing alcoholic beverages whose fermentation 5 period is shortened. Thus, according to the present invention, alcoholic beverages can be produced using existing facilities without increasing costs. 5. Method of assessing the yeast of the invention The method involves constructing an expression vector bearing the 10 polynucleotide obtained, introducing the vector into a yeast in a conventional manner and culturing the gene-transfected yeast in an oligosaccharide medium (e.g., a maltose/maltotriose medium). The aptitude of yeast can be evaluated by measuring the resistance to glucose-induced inactivation/degradation of the transporter contained in the yeast, the oligosaccharide assimilability, growth rate and 15 fermentation rate of the yeast in wort, etc during its incubation. The resistance to glucose-induced inactivation/degradation, oligosaccharide assimilability, growth rate, fermentation rate in wort, etc. can be assessed by the methods used in EXAMPLES later described. 20 EXAMPLES Hereinafter, the present invention will be described in more detail with reference to EXAMPLES but is not deemed to be limited thereto. Testing Methods: Test items and testing methods used in EXAMPLES are shown below. The 25 testing methods in EXAMPLES were performed basically in accordance with the methods below, unless otherwise indicated. <Acquisition of the MAL61, MAL31 and MAL21 genes> The MAL61 and MAL31 genes of yeast Saccharomyces cerevisiae were 30 already cloned and their nucleotide sequences were reported. MAL31 (SEQ ID NO: 3) used in the specification was obtained from the Saccharomyces Genome Database Accession No. YBR298C and MAL61 (SEQ ID NO: 5) from the GenBank Accession No. X17391. The MAL61 and MAL31 genes were obtained by amplifying the MAL6I and MAL3I genes by PCR using as a PCR temperate 35 chromosomal DNAs bearing the respective genes prepared from yeast 14 Saccharomyces cerevisiae based on information of their nucleotide sequences and isolating the genes. MAL21 of yeast Saccharomyces cerevisiae was known to be encoded by chromosome III but its DNA sequence was unknown. Taking into account that 5 MAL31 encoded by chromosome II and the MAL61 gene encoded by chromosome VIII have the identity of 99% or more, however, it was expected that MAL2I would have a considerably high identity. In fact, the inventors designed primers (5'AGAGCTCAGCATATAAAGAGACA 3' (SEQ ID NO: 7) and 10 5'TGGATCCGTATCTACCTACTGG 3' (SEQ ID NO: 8)) based on the DNA sequence of MAL61 obtained from GENBANK Accession No. X17391. Using as a template chromosomal DNA of yeast bearing the MAL21 gene but having no other ac-glucoside transporter gene, MAL21 could be obtained by PCR. Specifically, MAL31, MAL21 and MAL61 were obtained by PCR from Saccharomyces 15 cerevisiae S288C (ATCC 204508 (Rose, M.D., Winston, F. and Hieter, P., (1990), Methods in Yeast Genetics: A Laboratory Course Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY), Saccharomyces cerevisiae ATCC 20598 and Saccharomyces cerevisiae ATCC 96955, respectively, using the same primers. The DNA fragments obtained were inserted into vector pCR (registered trademark) 20 2.1-TOPO using TOPO TA cloning kit from Invitrogen Inc., followed b DNA sequencing to confirm the inserted gene sequences. It was confirmed that MAL31 and MAL61 were identical with the sequences registered in the data banks (Saccharomyces Genome Database Accession No. YBR298C and GenBank Accession No. X17391, respectively). For MAL21, 25 the sequence was determined by independently sequencing 10 clones or more (SEQ ID NO: 1). The primers used contain the Xbal or SacI site upstream of the initiation codon and the BamiHI site downstream of the termination codon, which are to be incorporated into an expression vector. Amplification of the target gene by PCR 30 using a chromosomal DNA and the following isolation can be performed by methods well known to those skilled in the art, including the preparation of PCR primers. The nucleotide sequence and amino acid sequence of MAL21 are shown in FIG 2 and FIG 3, respectively. 35 <Expression plasmid/plasmid for library construction> 15 In the present invention, the four expression vectors (1) to (4) were used. (1) pJHXSB (FIG. 10) (2) pJHIXSB (FIG 11) (3) pYCGPY (FIG 12) 5 (4) pUP3GLP(FIG 13) <Yeast strains> In the present invention, the strains (1) to (5) were used for acquisition of the transporter genes and for comparison among the strains, and the strains (6) to (8) 10 were used to confirm the growth rate and fermentation rate in strains with the transporters highly expressed. (1) S. cerevisiae S288C (ATCC 204508) (MATalpha SUC2 mal mel gal2 CUP 1) (2) S. cerevisiae ATCC 96955 (MATa MAL61 MAL62 MAL63 mal64 mal 1 MAL 12 mal13 ura3-52 leu2-3 leu2-112 trp l his) 15 (3) S. cerevisiae ATCC 20598 (MATa suc MAL2 MELI his4 leu2) (4) S. cerevisiae CB II (Berkley Stock Center) (MATa ade l MAL61 MAL62 MAL63 AGT1 MAL12 MAL31 MAL32) (5) S. cerevisiae HH1001 (MATa SUC2 mal mel gal2 CUP1 TPIl::TPIl pr-MAL32-G418R ura3) 20 (6) S. cerevisiae A152MS (MATa mal61::TRPI MAL62 MAL63 mal64 mall I MAL12 mal13 leu2-3 leu2-112 his URA3::TDH3p::MAL62) (7) Top-fermenting beer yeast: AH135 (8) Bottom-fermenting beer yeast: Weihenstephan 194 25 <Assessment of transporter protein on the maltose or maltotriose uptake activity> Expression of the introduced transporter gene in the transformant of a native transporter (which host is a strain carrying no cc-glucoside transporter gene) can be examined by the presence or absence of growth in the minimum medium containing 3 mg/L of antimycin using 0.5% maltose or maltotriose as the only carbon source 30 (6.7 g/L of yeast nitrogen base w/o amino acids, 5 g/L of maltose or maltotriose and 3 mg/L of antimycin). Even a strain which fails to function an a-glucoside transporter slightly grows on the minimum medium containing maltose or maltotriose as the only carbon source. However, when antimycin that is a respiration inhibitor is added, the strain cannot grow on the minimum medium 35 containing maltose or maltotriose as the only carbon source and the function of 16 a-glucoside transporter can be clearly confirmed. For example, one platinum loop of a test strain was taken out from a YPD plate (10 g/L of yeast extract, 20 g/L of polypeptone and 20 g/L of glucose), rinsed once in 1 ml of sterile water and then resuspended in sterile water adjusting to OD660 = 0.2. The cells were collected and 5 again suspended in 1 ml of sterile water. The cell suspension was directly streaked onto a test medium containing maltose or maltotriose as the only carbon source to examine the growth thereby to confirm the maltose or maltotriose uptake activity. <Assessment of transporter protein on 2-deoxyglucose resistance> 10 2-Deoxyglucose (2-DOG) is a sugar analog that is metabolized to 2-DOG-6-phosphate but not any further and cannot thus be a carbon source. However, it is known that 2-DOG induces glucose repression or glucose-induced inactivation to the same level as that of glucose. Accordingly, it is highly likely that strains growing on this plate would have a-glucoside transporters less susceptible to 15 glucose-induced inactivation. In order to evaluate the resistance to 2-DOQ plates with maltose minimum medium (6.7 g/L of yeast nitrogen base w/o amino acids, 20 g/L of maltose and 0-2.0 mM of 2-deoxyglucose) or maltose-containing synthetic complete medium (SCM) (6.7 g/L of yeast nitrogen base w/o amino acids, 20 g/L of maltose, 20 mg/ml of adenine sulfate, 20 mg/ml of uracil, 20 mg/ml of L-tryptophan, 20 20 mg/ml of L-histidine hydrochloride, 20 mg/ml of L-arginine hydrochloride, 20 mg/ml of L-methionine, 30 mg/ml of L-tyrosine, 30 mg/ml of L-leucine, 30 mg/ml of L-isoleucine, 30 mg/ml of L-lysine hydrochloride, 50 mg/ml of L-phenylalanine, 100 mg/ml of L-glutamic acid, 100 mg/ml of L-aspartic acid, 150 mg/ml of L-valine, 200 mg/ml of L-threonine and 400 mg/ml of L-serine) supplemented with 0 mM-2 mM 25 of 2-deoxyglucose (2-DOG) were prepared. A serial dilution of each transporter-expressed strain in the cell suspension at OD660=0.2 was spotted onto a test medium by 3 pl each and incubated at 30'C for 2 or 3 days for assessment. <Measurement of level of the transporter protein accumulated in cells > 30 The level of the transporter protein accumulated in cells can be assayed by, e.g., Western blotting. For example, a test strain is harvested from 10 ml of culture broth during the logarithmic growth phase and disrupted in a lysis buffer (8 M urea, 5 % (w/v) SDS, 40 mM Tris-HCl (pH 6.8), 0.1 mM EDTA, 1% 0-mercaptoethanol) by stirring with glass beads to give the cell extract. A total protein sample of 60 pg 35 was developed by SDS-gel electrophoresis and transferred onto a nitrocellulose 17 membrane followed by Western blotting using rabbit polyclonal anti-Mal6l p antibody. The rabbit polyclonal anti-Mal6lp antibody was obtained as follows. The procedures involve inserting a DNA encoding the N-terminal region (Metl-Leul81) of Mal6Ip into the pET Expression vector (Novagen) downstream of 5 GST tag in pET Expression vector (Novagen), transforming into Escherichia coli BL21 (DE3), applying a cell lysate of the transformant to a GST bind resin column and eluting the protein bound to the column. Full details are given in the manual attached to Novagen's pET Expression System, GST-Bind Affinity Resins (Novagen). The fused protein thus prepared was applied to SDS-PAGE to confirm 10 the purity. Then, rabbit was immunized using the fused protein as an immunogen to obtain the polyclonal antibody. Effectiveness of the antibody was confirmed by culturing the a-glucoside transporter gene-expressed yeast strain and its host strain free of the gene in a YPM medium (10 g/L of yeast extract, 20 g/L of polypeptone and 5.0 g/L of maltose) and subjecting the cell lysate to Western blotting using this 15 antibody according to the method described above. Positive bands consistent with the molecular weight of 68 kDa a-glucoside transporter were detected only in the yeast strain lysate in which the a-glucoside transporter gene was expressed. <Measurement of degradation rate of transporter protein> 20 The strain expressing each transporter protein was inoculated into YPD followed by shaking culture at 30 0 C overnight. The culture broth was inoculated into a YPM medium at OD660 = 1.0, shaking the cultured at 30'C for 2.5 hours and then collected. The 60 OD660 units of cells were measured and suspended in 30 ml of a medium for degradation rate measurement (1.6 g/L of yeast nitrogen base w/o 25 amino acids and ammonia, 20 g/L of glucose and 25 pg/L of cycloheximide) preincubated at 30*C, followed by incubation at 30'C. The cell suspension was sampled by 5 ml at an appropriate time (0, 10, 20, 30 and 40 minutes or 0, 30, 60, 90 and 120 minutes) immediately followed by centrifugation. The supernatant was discarded and the cells were frozen using an ethanol-dry ice. The transporter 30 protein was detected from the frozen cells by the method described above and the intensity of the protein band was measured to determine the half life from its diminution rate. <Assessment of maltose assimilability> 35 Assimilation of maltose by yeast constitutively expressing the transporter 18 protein can be evaluated by aerobically culturing or fermenting yeast under conditions suitable for the yeast and measuring the level of maltose in a medium. Sugars can be measured by methods well known to those skilled in the art, for example, liquid chromatography using an IR detector. In the transformed yeast 5 containing the nucleotide sequence of the present invention later described, the maltose uptake ability was improved. Example 1: Screening of a-glucoside transporter having the resistance to glucose-induced inactivation/degradation 10 Plates with 2% maltose-containing synthetic complete medium (SCM) supplemented with 0 mM to 2 mM of 2-deoxyglucose (2-DOG) were prepared. 2-DOG is a sugar analog that is metabolized to 2-DOG-6-phosphate but not any further and cannot thus be a carbon source. However, it is known that 2-DOG induces glucose repression or glucose-induced inactivation to the same level as 15 glucose. It is therefore highly likely that a strain grown on this plate would have an a-glucoside transporter less susceptible to glucose-induced inactivation. In a number of yeast strains, the cell suspension was spotted, followed by incubation at 30'C. As a result, M.AL2 1-bearing yeast strain ATCC 20598 grew even on the plate containing 1 mM of 2-DOG unlike the other strains, indicating that the strain was 20 predictably a transporter less susceptible to glucose-induced degradation (FIG 1). Accordingly, the primers (SEQ ID NOS: 7 and 8) were designed based on the nucleotide sequence information about 5' upstream and 3' downstream of MAL61 encoding gene. The MAL21 gene was amplified by PCR using the genomic DNA ATCC 20598 as a template and cloned into Invitrogen's pCR2. 1-TOPO followed by 25 DNA sequencing. The nucleotide sequence (SEQ ID NO: 1) and the amino acid sequence (SEQ ID NO: 2) are shown in FIGs. 2 and 3, respectively. Alignment of the amino acid sequence for Mal2Ip/Mal3 1p/Mal6Ip is shown in FIG. 4-1 and alignment of the nucleotide sequence of the nucleotide sequence in FIGS. 4-2 to 4-4. This MAL2I gene was incorporated into the SacI-BamHI site of plasmid 30 pJHIXSB (FIG. 11). After digesting with EcoRV in the URA3 gene, the plasmid pJHIMAL21 was incorporated into yeast HH100 1 as an expression unit constitutively transcribed by the TPII promoter, which was named HH206 strain. HH1001 is an ura3-sibling of the mal-strain X2180-1A and constitutively expresses maltase since TPI Ip::MAL32 (which encodes the maltase gene) is incorporated 35 therein. Growth of the HH206 strain was examined by applying the strain onto 19 SCM plates containing 0 mM to 2 mM of 2-DOG The HH108 and HH227 strains carrying the MAL61 and MAL31 genes could not grow on the 1.0 mM 2-DOG plate, whereas the HH206 strain grew on the 2.0 mM 2-DOG plate (FIG. 5). In addition, the glucose-induced degradation rate of Mal2 Ip was assayed by 5 Western blotting using anti-Mal6lp antibody. It was found that the half life was about 2 hours, whereas the half life of Mal3lp and Mal6lp was about 20 minutes. It was confirmed that Mal2 Ip had a much longer half life than the other transporters (FIG 6). 10 Example 2: Growth of MAL61-highly expressed strain and MAL21-highly expressed strain in maltose medium MAL61 and MAL21 were incorporated into plasmid pYCGPY at the SacI-BamHI site downstream of the PYKI promoter. The respective plasmids were named pYCGPYMAL61 and pYCGPYMAL21. The plasmid pYCGPY is a YCp 15 type plasmid bearing CEN-ARS and has a G418-resistant gene, an Ap-resistant gene, etc. (FIG 12). pYCGPYMAL61 and pYCGPYMAL21 were transformed into A152MS strain. The A152MS strain is a strain wherein MAL61 in ATCC 96955 is disrupted by TRP I marker and MAL62 (maltase gene) under control of the TDH3 promoter is introduced. A152MS (pYCGPYMAL61) and A152MS 20 (pYCGPYMAL2 1) were inoculated into YPM (10 g/L or yeast extract, 20 g/L or polypeptone and 5.0 g/L of maltose) to have OD660 = about 0.5, followed by shake culture at 30*C. The OD660 data was monitored every 1.5 hour (FIG 7). AI52MS (pYCGPYMAL21) grew more rapidly in maltose than A152MS (pYCGPYMAL6 I), and effects of the transporters having the resistance to 25 glucose-induced degradation were confirmed in the laboratory strains. Example 3: Test on happoshu (low-malt beer) wort fermentation by bottom-fermenting beer yeast where MAL21 was expressed at high level The transporter MAL21 having the resistance to glucose-induced 30 degradation was incorporated into plasmid pUP3GLP at the XbaI (or SacI)-BamHI site. pUP3GLP is shown in FIG 13. pUP3GLP is a YIp type plasmid, in which the transporter gene is expressed from glyceraldehyde triphosphate dehydrogenase promoter (TDH3p). After each plasmid was digested at the EcoRV site in URA3, the digestion product was transformed into bottom-fermenting beer yeast 35 (Weihenstephan 194) and the transformant was spread onto a YGP plate (10 g/L of 20 yeast extract, 20 g/L of polypeptone and 20 g/L of galactose) supplemented with 0.3 pg/ml of cycloheximide. The objective expression cassette was inserted into the URA3 gene on the chromosome of Weihenstephan 194, which was confirmed by PCR. 5 Weihenstephan 194 (URA3::TDH3p::MAL21) and parent strain Weihenstephan 194 were inoculated into two kinds of happoshu wort. The happoshu wort is a wort with less than 25% malt content in the raw materials except for water, in which glycosylated starch, hops, etc. are used. One of the worts for happoshu has an initial extract concentration of 14.0% and contains sugars in 10 proportions of 1.2% of glucose, 6.6% of maltose and 2.2% of maltotriose. Another glucose-rich happoshu wort has an initial extract concentration of 15.6% and contains sugars in proportions of 4.7% of glucose, 5.4% of maltose and 1.7% of maltotriose. Each wort was prepared by adding glycosylated starch having different sugar proportions to the same volume of wort (final concentration, less than 25% 15 malt content). Wet cells were pitched into each wort to become 7.5 g/L, which was allowed to ferment at 15*C. The maltose content in the moroni mash during the fermentation was measured. The results are shown in FIG. 8. In any happoshu wort, the assimilation rate of maltose in the MAL2 1-highly expressed strains was markedly faster than in the parent strain Weihenstephan 194. 20 Especially in the glucose-rich happoshu wort, its effect was remarkable. The high initial extract concentration means that the glucose content is high and the effect of the transporter having the resistance to glucose-induced degradation was fully observed. 25 EXAMPLE 4: Wort fermentation test by top-fermenting beer yeast in which MAL21 was highly expressed Glucose-induced degradation-resistant transporter MAL21 was incorporated into plasmid pUP3GLP at the XbaI (or SacI)-BamHI site. pUP3GLP is shown in FIG. 13. pUP3GLP is a YIp plasmid and the transporter gene is expressed by 30 glyceraldehyde triphosphate dehydrogenase promoter (TDH3p). After each plasmid was digested at the EcoRV site in URA3, the digestion product was transformed into top-fermenting yeast AH135 and the transformant was spread onto a YPG plate (10 g/L of yeast extract, 20 g/L of polypeptone and 20 g/L of galactose) supplemented with 0.3 pg/ml of cycloheximide. It was confirmed by PCR that the 35 objective expression cassette was inserted into the URA3 gene on the chromosome 21 ofAH135. AH135 (URA3::TDH3p::MAL21) was pitched into a 100% malt wort with an initial extract concentration of 13% or 20% containing as the initial extract concentration adjusted to 5 g/L of wet cells. Fermentation was conducted at 15 0 C and the maltose concentration in the mash during fermentation was measured. The 5 results are shown in FIG 9. The maltose assimilation rate was faster than the parent strain AH1135 even using either strain. Especially in the initial extract concentration of 20%, its effect was remarkable. The initial extract concentration being high indicates that the glucose concentration is high, meaning that the transporter having the resistance to 10 glucose-induced degradation was effective. It was confirmed that the high level expression of the transporter having the resistance to glucose-induced degradation was effective not only for the bottom-fermenting beer yeast but also for top-fermenting beer yeast. 15 As described above, it has been found that Mal21 p naturally present in some yeasts is less susceptible to glucose-induced degradation, unlike other ot-glucoside transporters. It has also been confirmed that assimilation of sugars such as maltose in mash, etc. taken up by the transporter can be accelerated by using yeasts (irrespective of laboratory strains or brewing yeasts) capable of expressing the 20 transporter. Especially when the concentration of monosaccharides such as glucose is high, the effects are more prominent. INDUSTRIAL APPLICABILITY The yeast bearing the transporter in accordance with the present invention 25 which has the resistance to glucose-induced inactivation/degradation provides improved oligosaccharide assimilability and is excellent in its ability to assimilate sugars such as maltose, etc.. Such yeast can be effectively used in brewing beer or wine. 22
Claims (15)
1. An isolated polynucleotide selected from the group consisting of (a) to (c) below: 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1; (b) a polynucleotide comprising a nucleotide sequence encoding a protein consisting of the amino acid sequence of SEQ ID NO: 2; and (c) a polynucleotide comprising a nucleotide sequence encoding an alpha Glucoside transporter protein comprising an amino acid sequence having an identity of 10 at least 99% with the amino acid sequence of SEQ ID NO: 2, wherein said alpha Glucoside transporter protein has a resistance to glucose-induced inactivation and/or degradation, and said alpha-Glucoside transporter protein has maltose or maltoritose uptacke activity.
2. The isolated polynucleotide according to claim 1, wherein said polynucleotide 15 comprising a nucleotide sequence encoding an alpha-Glucoside transporter protein comprising the amino acid sequence having an identity of at least 99.5% with the amino acid sequence of SEQ ID NO: 2.
3. The polynucleotide according to claim 1 or 2, comprising a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 1. 20
4. The polynucleotide according to claim I or 2, comprising a polynucleotide encoding a protein consisting of the amino acid sequence of SEQ ID NO: 2.
5. The polynucleotide according to any one of claims I to 4, which is a DNA.
6. A protein encoded by the polynucleotide according to any one of claims I to 5.
7. A vector comprising the polynucleotide according to any one of claims I to 5. 25
8. A transformed yeast introduced with the vector according to claim 7.
9. The yeast for brewing according to claim 8, wherein oligosaccharide assimilability is enhanced by introducing said vector.
10. The yeast for brewing according to claim 9, wherein oligosaccharide assimilability is enhanced by increasing the expression level of a polynucleotide 30 selected from the group consisting of (a) to (c) below: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:l; (b) a polynucleotide comprising a nucleotide sequence encoding a protein consisting of the amino acid sequence of SEQ ID NO:2; and (c) a polynucleotide comprising a nucleotide sequence encoding an alpha 35 Glucoside transporter protein comprising an amino acid sequence having an identity of at least 99% with the amino acid sequence of SEQ ID NO:2, wherein said alpha 628666 1 24 Glucoside transporter protein has a resistance to glucose-induced inactivation and/or degradation, said alpha-Glucoside transporter protein has maltose or maltoritose uptake activity.
11. A method of producing an alcoholic beverage which comprises using the yeast 5 according to any one of claims 8 to 10.
12. The method of producing an alcoholic beverage according to claim 11, wherein the alcoholic beverage brewed is a malt beverage.
13. The method of producing an alcoholic beverage according to claim 12, wherein the alcoholic beverage brewed is wine. 10
14. An alcoholic beverage produced by the method according to any one of claims 11 to 13.
15. An isolated polnucleotide according to claim I or 2, a protein according to claim 6, a vector according to claim 7, or a yeast according to claim 8, substantially as described herein with reference to the figures and/or examples, excluding comparative 15 examples. 628666 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008297027A AU2008297027B2 (en) | 2008-09-09 | 2008-09-09 | Glucose-induced inactivation/degradation-resistant transporter gene and use thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008297027A AU2008297027B2 (en) | 2008-09-09 | 2008-09-09 | Glucose-induced inactivation/degradation-resistant transporter gene and use thereof |
| PCT/JP2008/066241 WO2010029612A1 (en) | 2008-09-09 | 2008-09-09 | Glucose-induced inactivation/degradation resistance transporter gene and use of the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2008297027A1 AU2008297027A1 (en) | 2010-03-25 |
| AU2008297027B2 true AU2008297027B2 (en) | 2011-08-18 |
Family
ID=42041481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008297027A Ceased AU2008297027B2 (en) | 2008-09-09 | 2008-09-09 | Glucose-induced inactivation/degradation-resistant transporter gene and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2008297027B2 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0306107A2 (en) * | 1987-09-03 | 1989-03-08 | Gist-Brocades N.V. | New yeast strains providing for an enhanced rate of the fermentation of sugars, a process to obtain such yeasts and the use of these yeats |
| JPH06245750A (en) * | 1993-02-26 | 1994-09-06 | Suntory Ltd | Beer manufacturing method |
-
2008
- 2008-09-09 AU AU2008297027A patent/AU2008297027B2/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0306107A2 (en) * | 1987-09-03 | 1989-03-08 | Gist-Brocades N.V. | New yeast strains providing for an enhanced rate of the fermentation of sugars, a process to obtain such yeasts and the use of these yeats |
| JPH06245750A (en) * | 1993-02-26 | 1994-09-06 | Suntory Ltd | Beer manufacturing method |
Non-Patent Citations (6)
| Title |
|---|
| CHENG, Q. et al., Genetics, 1989, vol. 123, pages 477-484 * |
| DAY, R. E. et al., Yeast, 2002, Vol. 19, pages 1015-1027 * |
| DIETVORST, J. et al., Yeast, 2005, vol. 22, pages 775-788 * |
| FEUERMANN, M. et al., Yeast, 1995, vol. 11, pages 667-672 * |
| KODAMA, Y. et al., J. Am. Soc. Brew. Chem., 1995, vol. 53, pages 24-29 * |
| YAO, B. et al., Gene, 1989, Vol. 79, pages 189-197 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008297027A1 (en) | 2010-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007223598B2 (en) | Glycerol-3-phosphate dehydrogenase gene and use thereof | |
| US20140248689A1 (en) | Glucose-induced inactivation/degradation-resistant transporter gene and use thereof | |
| US8053224B2 (en) | Glucose-induced inactivation/degradation-resistant transporter gene and use thereof | |
| US8048667B2 (en) | Hybrid alpha-glucoside transporter | |
| AU2008297027B2 (en) | Glucose-induced inactivation/degradation-resistant transporter gene and use thereof | |
| JP5241771B2 (en) | Glucose-induced inactivation / degradation resistance transporter gene and use thereof | |
| AU2008297026B2 (en) | Hybrid alpha-glucoside transporter | |
| CA2638791A1 (en) | Gene encoding transcriptional inducer for maltase gene and maltose transporter gene and use thereof | |
| JP4954203B2 (en) | Gene encoding cell wall mannoprotein and use thereof | |
| AU2007223596B2 (en) | Gene encoding glycogen synthesis initiator and use thereof | |
| CA2638762A1 (en) | Ammonia transporter gene and use thereof | |
| JP2009011160A (en) | Gene encoding cell wall mannoprotein and use of the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: SUNTORY HOLDINGS LIMITED Free format text: FORMER APPLICANT(S): SUNTORY LIMITED |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |